Sprott’s NervGen Pharma NGEN Stock Holding History
Bought
Maintained
Sold
Other funds holding NGEN
Sprott's NGEN Position: Q3 2026 in Review
Sprott held its NervGen Pharma (NGEN) position steady in Q3 2026 at 25,000 shares worth $47.8K. The position accounts for ﹤0.01% of the portfolio, ranked #249.
Sprott first reported a position in NGEN in Q1 2026 and has held it in 3 quarters since. The position peaked at $94.2K in Q1 2026. 49 funds tracked by Wall St. Rank hold NGEN as of Q3 2026.
- Sprott held 25,000 shares of NervGen Pharma worth $47.8K as of Q3 2026.
- Sprott left its NervGen Pharma share count unchanged in Q3 2026.
- NervGen Pharma made up ﹤0.01% of Sprott's portfolio in Q3 2026, its #249 holding.
- Sprott first reported a position in NervGen Pharma in Q1 2026 and has held it in 3 quarters since.
- Sprott's NervGen Pharma position peaked at $94.2K in Q1 2026.
- 49 funds tracked by Wall St. Rank held NervGen Pharma as of Q3 2026.
Based on Sprott's 13F filing for Q3 2026, filed 9 Nov 2026.